Cargando…

Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer

BACKGROUND: Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [(18)F]PSMA-1007-PET/CT in patients with biochemically recurrent PCa and id...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmadi Bidakhvidi, Niloefar, Laenen, Annouschka, Jentjens, Sander, Deroose, Christophe M., Van Laere, Koen, De Wever, Liesbeth, Mai, Cindy, Berghen, Charlien, De Meerleer, Gert, Haustermans, Karin, Joniau, Steven, Everaerts, Wouter, Goffin, Karolien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087750/ https://www.ncbi.nlm.nih.gov/pubmed/33929626 http://dx.doi.org/10.1186/s13550-021-00783-w

Ejemplares similares

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial
por: Berghen, Charlien, et al.
Publicado: (2020)

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
por: Devos, Gaëtan, et al.
Publicado: (2020)

Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
por: Berghen, Charlien, et al.
Publicado: (2020)

Value of [(68)Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature
por: Deleu, Anne-Leen, et al.
Publicado: (2022)

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
por: Rans, Kato, et al.
Publicado: (2022)

Intra-individual qualitative and quantitative comparison of [(68)Ga]Ga-DOTATATE PET/CT and PET/MRI
por: Lens, Géraldine, et al.
Publicado: (2023)

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
por: Tosco, Lorenzo, et al.
Publicado: (2018)

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
por: Ahmadi Bidakhvidi, Niloefar, et al.
Publicado: (2021)

(18)F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study
por: Emonds, Kimy M, et al.
Publicado: (2013)

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer
por: Devos, Gaëtan, et al.
Publicado: (2019)

Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial
por: Draulans, Cédric, et al.
Publicado: (2018)

Accuracy of dynamic sentinel lymph node biopsy for inguinal lymph node staging in cN0 penile cancer
por: Gebruers, Juanito, et al.
Publicado: (2023)

Anatomical mapping of lymph nodes in patients receiving salvage lymphadenectomy based on a positive 11C-choline positron emission tomography/computed tomography scan
por: Deconinck, Steven, et al.
Publicado: (2019)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Nine-year survival after iterative metastasectomies for renal cell carcinoma
por: de Oliveira, Tiago Ribeiro, et al.
Publicado: (2019)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

On the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone
por: De Coster, Liesbeth, et al.
Publicado: (2018)

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility
por: Mamlins, E., et al.
Publicado: (2022)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Simultaneous (18)F-FDG PET/MR metabolic and structural changes in visual snow syndrome and diagnostic use
por: Van Laere, Koen, et al.
Publicado: (2022)

Standardized 4-point scoring scale of [(18)F]-FDG PET/CT imaging helps in the diagnosis of renal and hepatic cyst infections in patients with autosomal dominant polycystic kidney disease: a validation cohort
por: Demuynck, Selina, et al.
Publicado: (2023)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

[(18)F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue
por: Di Iorio, Valentina, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation
por: Ambrosini, Valentina, et al.
Publicado: (2023)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

[(18)F]PSMA‐1007 renal uptake parameters: Reproducibility and relationship to estimated glomerular filtration rate
por: Valind, Kristian, et al.
Publicado: (2022)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gva3r4rd89b92b70jchv3p3bl2